Skip to Content
scroll

Resmed (RMD) $30.70

RMD -9.31%: Hit hard today after reporting 4Q23 earnings overnight in the US that were softer than expected. A combination of slightly softer revenue, lower gross margin and higher costs created a weaker than anticipated result. Adjusted EPS of $1.60 was higher than last year ($1.49) but below consensus of  $1.70. Revenue was up 23% to $1.12bn  but below the $1.13bn expected with that issue compounded by a gross margin of 55% vs. 57.1% last year and estimate of 56.5%. While the result is light on, they are still delivering strong top line growth as demand continues for their products – margins as issue which leads to reasonable reductions in valuation in outer years.

  • We own RMD and do not intend to sell it given the sharp decline.
RMD
MM is now neutral RMD following todays result
Add To Hit List
chart
image description
ResMed Inc (RMD)
image description

Relevant suggested news and content from the site

Back to top